TY - JOUR
T1 - Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
AU - Schmid, Christoph
AU - Labopin, Myriam
AU - Nagler, Arnon
AU - Niederwieser, Dietger
AU - Castagna, Luca
AU - Tabrizi, Reza
AU - Stadler, Michael
AU - Kuball, Jürgen
AU - Cornelissen, Jan
AU - Vorlicek, Jiri
AU - Socié, Gerard
AU - Falda, Michele
AU - Vindeløv, Lars
AU - Ljungman, Per
AU - Jackson, Graham
AU - Kröger, Nicolaus
AU - Rank, Andreas
AU - Polge, Emmanuelle
AU - Rocha, Vanderson
AU - Mohty, Mohamad
PY - 2012
Y1 - 2012
N2 - Since information on management and outcome of adults with AML relapsing after allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning (RIC HSCT) is scarce, a retrospective registry study was performed by the Acute Leukemia Working Party of EBMT. Among 2815 RIC transplants performed for AML in CR between 1999 and 2008, cumulative incidence of relapse was 32±1%. Data from 263 relapsed patients were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was re-induced in 32%, remission duration after transplantation was the only prognostic factor for response (p=.003). Estimate 2y-OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at time of relapse, remission after HSCT >5 months (HR=.50, 95%CI=.37-.67, p
AB - Since information on management and outcome of adults with AML relapsing after allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning (RIC HSCT) is scarce, a retrospective registry study was performed by the Acute Leukemia Working Party of EBMT. Among 2815 RIC transplants performed for AML in CR between 1999 and 2008, cumulative incidence of relapse was 32±1%. Data from 263 relapsed patients were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was re-induced in 32%, remission duration after transplantation was the only prognostic factor for response (p=.003). Estimate 2y-OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at time of relapse, remission after HSCT >5 months (HR=.50, 95%CI=.37-.67, p
U2 - 10.1182/blood-2011-08-375840
DO - 10.1182/blood-2011-08-375840
M3 - Journal article
C2 - 22167752
SN - 0006-4971
VL - 119
SP - 1599
EP - 1606
JO - Blood
JF - Blood
IS - 6
ER -